Literature DB >> 18704682

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.

Simon A Joosse1, Erik H van Beers, Ivon H G Tielen, Hugo Horlings, Johannes L Peterse, Nicoline Hoogerbrugge, Marjolijn J Ligtenberg, Lodewyk F A Wessels, Priscilla Axwijk, Senno Verhoef, Frans B L Hogervorst, Petra M Nederlof.   

Abstract

BACKGROUND: While new defects in BRCA1 are still being found, it is unclear whether current breast cancer diagnostics misses many BRCA1-associated cases. A reliable test that is able to indicate the involvement of BRCA1 deficiency in cancer genesis could support decision making in genetic counselling and clinical management. To find BRCA1-specific markers and explore the effectiveness of the current diagnostic strategy, we designed a classification method, validated it and examined whether we could find BRCA1-like breast tumours in a group of patients initially diagnosed as non-BRCA1/2 mutation carriers.
METHODS: A classifier was built based on array-CGH profiles of 18 BRCA1-related and 32 control breast tumours, and validated on independent sets of 16 BRCA1-related and 16 control breast carcinomas. Subsequently, we applied the classifier to 48 breast tumours of patients from Hereditary Breast and Ovarian Cancer (HBOC) families in whom no germ line BRCA1/BRCA2 mutations were identified.
RESULTS: The classifier showed an accuracy of 91% when applied to the validation sets. In 48 non-BRCA1/2 patients, only two breast tumours presented a BRCA1-like CGH profile. Additional evidence for BRCA1 dysfunction was found in one of these tumours.
CONCLUSION: We here describe the specific chromosomal aberrations in BRCA1-related breast carcinomas. We developed a predictive genetic test for BRCA1-association and show that BRCA1-related tumours can still be identified in HBOC families after routine DNA diagnostics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704682     DOI: 10.1007/s10549-008-0117-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  49 in total

1.  BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes.

Authors:  Simon A Joosse
Journal:  Nat Rev Cancer       Date:  2012-05-24       Impact factor: 60.716

2.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Authors:  Helen Davies; Dominik Glodzik; Sandro Morganella; Lucy R Yates; Johan Staaf; Xueqing Zou; Manasa Ramakrishna; Sancha Martin; Sandrine Boyault; Anieta M Sieuwerts; Peter T Simpson; Tari A King; Keiran Raine; Jorunn E Eyfjord; Gu Kong; Åke Borg; Ewan Birney; Hendrik G Stunnenberg; Marc J van de Vijver; Anne-Lise Børresen-Dale; John W M Martens; Paul N Span; Sunil R Lakhani; Anne Vincent-Salomon; Christos Sotiriou; Andrew Tutt; Alastair M Thompson; Steven Van Laere; Andrea L Richardson; Alain Viari; Peter J Campbell; Michael R Stratton; Serena Nik-Zainal
Journal:  Nat Med       Date:  2017-03-13       Impact factor: 53.440

3.  Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.

Authors:  Na Li; Simone McInerny; Magnus Zethoven; Dane Cheasley; Belle W X Lim; Simone M Rowley; Lisa Devereux; Norah Grewal; Somayeh Ahmadloo; David Byrne; Jue Er Amanda Lee; Jason Li; Stephen B Fox; Thomas John; Yoland Antill; Kylie L Gorringe; Paul A James; Ian G Campbell
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

4.  Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.

Authors:  Sean P Pitroda; Riyue Bao; Jorge Andrade; Ralph R Weichselbaum; Philip P Connell
Journal:  Clin Cancer Res       Date:  2017-03-24       Impact factor: 12.531

Review 5.  Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Authors:  Marieke A Vollebergh; Jos Jonkers; Sabine C Linn
Journal:  Cell Mol Life Sci       Date:  2011-09-16       Impact factor: 9.261

6.  Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.

Authors:  Rosa Murria Estal; Sarai Palanca Suela; Inmaculada de Juan Jiménez; Cristina Alenda Gonzalez; Cecilia Egoavil Rojas; Zaida García-Casado; Jose Antonio López Guerrero; María José Juan Fita; Ana Beatriz Sánchez Heras; Ángel Segura Huerta; Ana Santaballa Bertrán; Isabel Chirivella González; Marta Llop García; Gema Pérez Simó; Eva Barragán González; Pascual Bolufer Gilabert
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

7.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.

Authors:  M T Branham; E Campoy; S Laurito; R Branham; G Urrutia; J Orozco; F Gago; R Urrutia; M Roqué
Journal:  Breast Cancer Res Treat       Date:  2015-11-27       Impact factor: 4.872

9.  Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes.

Authors:  Lorenzo Melchor; Laura Paula Saucedo-Cuevas; Iván Muñoz-Repeto; Socorro María Rodríguez-Pinilla; Emiliano Honrado; Alfredo Campoverde; Jose Palacios; Katherine L Nathanson; María José García; Javier Benítez
Journal:  Breast Cancer Res       Date:  2009-12-08       Impact factor: 6.466

10.  Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.

Authors:  Logan C Walker; Bryony A Thompson; Nic Waddell; Sean M Grimmond; Amanda B Spurdle
Journal:  PLoS Genet       Date:  2010-02-19       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.